Postpartum Depression Diagnostic Algorithm: Step by Step

What Postpartum Depression Actually Is (and Is Not)

Postpartum depression is a major depressive episode with peripartum onset. The DSM-5 specifier "with peripartum onset" applies when symptoms begin during pregnancy or within four weeks of delivery, though ACOG Practice Bulletin 222 and most practicing clinicians extend that window to 12 months postpartum because that is when most cases present clinically.

PPD is not the postpartum blues. The blues affect up to 80% of new mothers, peak around day 3-5 as progesterone and estrogen fall sharply after placental delivery, and resolve on their own within two weeks. If low mood, tearfulness, or irritability persists beyond two weeks or is severe enough to impair daily function, the diagnosis shifts to PPD and requires active management.

Why Sex-Specific Physiology Matters Here

The dramatic drop in estradiol and progesterone after delivery, from pregnancy-peak levels to near-menopausal levels within 24-72 hours, is the likely neurobiological trigger for a subset of women with PPD. Research published in JAMA Psychiatry found that women with PPD show heightened neurological sensitivity to allopregnanolone fluctuations, a progesterone metabolite that modulates GABA-A receptors, compared with postpartum women who do not develop depression. This is the exact mechanism that brexanolone and zuranolone target.

Thyroid dysfunction is a separate but overlapping risk. Postpartum thyroiditis affects 5-10% of postpartum women and can mimic or worsen depression; ruling it out is part of the workup.

Step 1: Universal Screening with the EPDS

Universal screening is the standard of care. The USPSTF 2019 recommendation calls for providing or referring pregnant and postpartum women to counseling interventions after positive screening, and ACOG recommends that all obstetric providers screen at least once during the perinatal period using a validated tool.

The Edinburgh Postnatal Depression Scale

The EPDS is a 10-item self-report questionnaire developed specifically for the perinatal population. It takes about 5 minutes to complete and is validated in more than 23 languages.

Scoring interpretation:

| EPDS Score | Clinical Action | |---|---| | 0-9 | Low concern; rescreen at next visit | | 10-12 | Possible depression; clinical interview indicated | | ≥13 | Probable major depression; immediate evaluation | | Any score with item 10 > 0 | Active suicidal ideation; same-day safety assessment |

Item 10 asks directly about self-harm thoughts. Any positive response on item 10 requires immediate safety evaluation regardless of total score. A 2020 meta-analysis in the British Journal of General Practice confirmed an EPDS cut-off of ≥13 yields sensitivity of 0.81 and specificity of 0.87 for major depressive disorder in postpartum women.

When to Screen

• At the first prenatal visit (depression during pregnancy predicts PPD)
• At 28-32 weeks gestation
• At the postpartum visit, now recommended at 3 weeks, 6 weeks, and the infant's 2-month and 4-month well-child visits per ACOG guidance

Step 2: Clinical Interview and DSM-5 Criteria

A positive EPDS is a trigger, not a diagnosis. The next step is a structured clinical interview using DSM-5 criteria for major depressive episode with peripartum onset specifier.

DSM-5 Criteria You Need to Meet

Five or more of the following nine symptoms must be present for at least two weeks, with at least one being depressed mood or loss of interest:

1. Depressed mood most of the day, nearly every day
2. Markedly diminished interest or pleasure in activities
3. Significant weight change or appetite disturbance (note: postpartum weight changes complicate this criterion)
4. Insomnia or hypersomnia (note: infant sleep disruption complicates this criterion)
5. Psychomotor agitation or slowing
6. Fatigue or loss of energy
7. Feelings of worthlessness or excessive guilt, often centered on motherhood adequacy
8. Difficulty concentrating or making decisions
9. Recurrent thoughts of death or suicidal ideation

Two criteria, sleep disruption and appetite changes, are confounded by new parenthood itself. Experienced clinicians weight the remaining seven symptoms more heavily when building the picture. A structured review in Archives of Women's Mental Health specifically highlighted this diagnostic challenge and recommended anchoring the interview to guilt, anhedonia, and psychomotor symptoms rather than sleep alone.

Validated Adjunct Tools

• PHQ-9: Widely used in primary care; cut-off of ≥10 for major depression. Less validated in postpartum specifically than EPDS but acceptable.
• Beck Depression Inventory-II (BDI-II): Used in research settings; score ≥17 indicates moderate depression.

Step 3: Differential Diagnosis, the Conditions You Must Rule Out

Not every low mood after delivery is PPD. Working through the differential protects against both under-treatment and misdiagnosis.

Postpartum Anxiety

Up to 17% of postpartum women meet criteria for an anxiety disorder, and anxiety often co-occurs with depression. Generalized anxiety, panic disorder, and OCD with intrusive thoughts about harming the baby are all distinct conditions that require their own management. The EPDS anxiety subscale (items 3, 4, 5) can help flag this.

Postpartum Psychosis

Postpartum psychosis is a psychiatric emergency. It affects 1-2 per 1,000 deliveries and typically presents within the first two weeks postpartum with rapid-onset hallucinations, delusions, and disorganized behavior. Women with bipolar disorder face a risk as high as 25-50% for postpartum psychosis. Any psychotic features require immediate psychiatric referral and hospitalization, not outpatient PPD management.

Postpartum Thyroiditis

Order TSH, free T4, and thyroid peroxidase antibodies for any woman with depressive symptoms postpartum. Hypothyroid phase typically occurs 4-8 months after delivery and is easily missed. The American Thyroid Association guidelines recommend thyroid function testing in symptomatic postpartum women.

Bipolar Disorder

A depressive episode with mixed features, hypomanic history, or strong family history of bipolar disorder requires mood stabilizer evaluation before starting an antidepressant alone, because antidepressant monotherapy can destabilize cycling. Ask directly about past periods of decreased need for sleep, racing thoughts, or unusually elevated energy.

Iron Deficiency Anemia

Postpartum hemorrhage and iron depletion from pregnancy itself can cause fatigue and low mood that mimics depression. Check a CBC and ferritin, particularly if blood loss was significant.

Step 4: Severity Rating and Risk Stratification

Once PPD is confirmed, severity guides the treatment decision tree.

WomanRx PPD Severity-to-Treatment Decision Framework:

| Severity | Features | First-Line Approach | |---|---|---| | Mild (EPDS 10-12, PHQ-9 5-9) | Functional impairment minimal | Structured psychotherapy (CBT or IPT); monitor weekly | | Moderate (EPDS 13-19, PHQ-9 10-19) | Impaired daily function, bonding affected | Psychotherapy PLUS antidepressant or zuranolone | | Severe (EPDS ≥20, PHQ-9 ≥20) | Cannot care for infant, suicidal ideation | Antidepressant (rapid titration) plus urgent psychiatry; consider hospitalization | | Any severity with psychotic features | Hallucinations, delusions | Emergency psychiatric referral |

Risk stratification also includes social determinants: lack of partner support, housing instability, prior depressive episodes, and a history of trauma all increase severity and chronicity, regardless of symptom count.

Step 5: Treatment Options, Matched to Your Life Stage and Feeding Choice

Treatment for PPD is not one-size-fits-all. Your decision depends on whether you are breastfeeding, the severity of symptoms, prior medication response, and how quickly you need relief.

Psychotherapy: First-Line for Mild to Moderate PPD

Cognitive behavioral therapy (CBT) and interpersonal therapy (IPT) are both evidence-based for PPD. A 2018 Cochrane review of 28 randomized trials found psychological interventions significantly reduced PPD symptoms compared with standard care (SMD -0.36, 95% CI -0.49 to -0.22). IPT is particularly well-suited to the role-transition stress of new motherhood and targets the relationship changes that accompany a new baby.

Telehealth delivery of CBT has shown similar efficacy to in-person therapy in postpartum women, which matters for women who cannot easily leave home with a newborn.

Antidepressants: SSRIs as the Backbone of Pharmacotherapy

For moderate to severe PPD, or when psychotherapy alone is insufficient, SSRIs are the pharmacological workhorse.

Sertraline is the most studied SSRI in the postpartum period. A landmark study by Wisner et al. In JAMA showed sertraline significantly reduced PPD symptoms versus placebo at 8 weeks. Breast-milk transfer is low (relative infant dose approximately 0.5-3%), and infant serum levels are typically undetectable.

Paroxetine also has very low breast-milk transfer, though its short half-life makes missed doses harder to manage in the sleep-deprived postpartum period. The LactMed database classifies both sertraline and paroxetine as preferred SSRIs during lactation.

Escitalopram and fluoxetine have more breast-milk transfer than sertraline. Fluoxetine in particular has a long-acting metabolite (norfluoxetine) and is generally not preferred in women nursing newborns, though it is not absolutely contraindicated.

Response typically takes 4-6 weeks for full effect. Do not discontinue before 6 months given the risk of relapse.

Zuranolone: The First Oral PPD-Specific Treatment

In August 2023, the FDA approved zuranolone (Zurzuvae) 50 mg as the first oral neuroactive steroid specifically approved for PPD. The drug is a GABA-A positive allosteric modulator that acts on the same allopregnanolone pathway implicated in the neurobiology of PPD.

The key SKYLARK trial showed that a 14-day course of zuranolone 50 mg once nightly produced a significant reduction in HAMD-17 total score at day 15 (least-squares mean difference -4.2 points, p < 0.001) compared with placebo, with response maintained at day 45. This speed of response, two weeks versus four to six weeks for SSRIs, is clinically meaningful when bonding with a newborn is at stake.

Zuranolone carries a boxed warning for somnolence and CNS depression. Women must not drive or operate heavy machinery for at least 12 hours after each dose. It is Schedule IV controlled substance in the United States.

Lactation note: Zuranolone passes into breast milk. The prescribing information advises women to consider pumping and discarding milk during the 14-day course, or to weigh the decision with their provider based on breastfeeding goals and symptom severity. Data on infant exposure are limited.

Brexanolone: IV Option for Severe PPD

Brexanolone (Zulresso) was the first FDA-approved PPD-specific treatment (2019) and acts via the same allopregnanolone mechanism. It requires a 60-hour continuous IV infusion in a certified healthcare facility due to risk of sudden loss of consciousness. The HUMMINGBIRD trials showed significant improvement in HAM-D scores at 60 hours versus placebo. Access remains limited due to the REMS program and infusion requirement; zuranolone has largely replaced it as the preferred neuroactive steroid option for most women.

Hormonal Considerations

The evidence for estradiol as a PPD treatment is preliminary. A 1996 RCT by Gregoire et al. In The Lancet showed transdermal estradiol 200 mcg improved PPD symptoms over 3 months, but estradiol is not currently an approved PPD treatment, inhibits lactation at high doses, and increases thromboembolic risk in the early postpartum period. It is not recommended outside a research setting at this time.

Pregnancy and Lactation Safety: What Every Woman Deserves to Know

Drug safety in the perinatal period is where the evidence gaps are largest and where women most often receive incomplete information.

Antidepressants During Pregnancy

All major antidepressants are FDA Pregnancy Category C (old system) or carry specific label language. The question is not whether to treat, but whether the risks of untreated depression outweigh medication risks.

ACOG Practice Bulletin 92 states plainly that untreated depression in pregnancy carries its own risks, including preterm birth, low birth weight, poor prenatal care adherence, and postpartum bonding difficulties. Stopping antidepressants abruptly in the first trimester without a plan is not automatically the safer choice.

SSRIs taken in the third trimester can cause transient neonatal adaptation syndrome (jitteriness, respiratory distress, feeding difficulties lasting 2-6 days). This is not a reason to stop medication in the third trimester; it requires coordinating with the neonatal team so monitoring is in place. A large study in JAMA Pediatrics found no increased risk of serious adverse neonatal outcomes attributable to late-pregnancy SSRI exposure after controlling for confounders.

Paroxetine has historically been labeled with a cardiovascular malformation signal in the first trimester; while the absolute risk remains small, sertraline is generally preferred for women starting medication during pregnancy.

Lactation Transfer Summary

| Drug | Relative Infant Dose | LactMed Classification | |---|---|---| | Sertraline | 0.5-3% | Preferred | | Paroxetine | <2% | Preferred | | Escitalopram | 3-8% | Compatible with monitoring | | Fluoxetine | 6-9% (plus active metabolite) | Use with caution in newborns | | Zuranolone | Unknown; present in breast milk | Discuss with provider; consider pump-and-dump | | Brexanolone | Present in breast milk | Discuss with provider |

Women deserve a conversation about these numbers, not a blanket instruction to stop breastfeeding if they need medication.

Who This Approach Is Right For, and Who Needs a Different Path

Reproductive Years (Postpartum, First Episode)

The algorithm described here is built for this group. Start with EPDS, complete the clinical interview, rule out thyroid disease and bipolar disorder, and choose therapy, pharmacotherapy, or both based on severity. If this is a first depressive episode and the postpartum trigger is clear, many women can taper off antidepressants at 6-12 months with close monitoring.

Women with Prior PPD or Recurrent Depression

Recurrence risk after one episode of PPD is 40-50% with subsequent deliveries. Prophylactic sertraline started immediately postpartum (day 1) has evidence supporting its use in women with a prior PPD history. Discuss this plan explicitly during the third trimester.

Trying to Conceive

If you are planning a pregnancy and currently on an antidepressant for PPD or recurrent depression, do not stop abruptly. Sertraline is the preferred SSRI to continue through conception and pregnancy planning given its safety profile. Discuss a tapering plan with your provider only if your mood has been stable for 6-12 months.

Perimenopause and Beyond

A history of PPD is a significant risk factor for perimenopausal depression. Research published in JAMA Psychiatry found that women with a past perinatal depressive episode were more than twice as likely to develop depression during perimenopause, likely reflecting an underlying sensitivity to hormone flux. If you experienced PPD and are now approaching perimenopause with mood changes, tell your provider about your PPD history explicitly because it changes the differential and the approach.

When to Seek Help Today

The single most common reason PPD goes untreated is that women delay, either waiting to see if things improve or feeling ashamed to report symptoms. Seek evaluation same-day or go to an emergency department if any of the following are present:

• Thoughts of harming yourself or your baby (even thoughts you know you would never act on)
• Inability to sleep even when the baby sleeps for two or more consecutive nights
• Auditory or visual hallucinations
• Feeling like your baby would be better off without you
• Rapid mood swings or feeling like you are losing your mind

If your EPDS score is ≥13 or your PHQ-9 is ≥10 at a routine visit, ask your provider for an immediate clinical interview, not a referral with a 6-week wait.